Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Ascendis Pharma

DB:A71
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
A71
DB
$6B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
  • Ascendis Pharma has significant price volatility in the past 3 months.
A71 Share Price and Events
7 Day Returns
15.9%
DB:A71
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
7.6%
DB:A71
-7.4%
DE Biotechs
-14.2%
DE Market
A71 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ascendis Pharma (A71) 15.9% -0.9% -9.6% 7.6% 339.3% 581.5%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • A71 outperformed the Biotechs industry which returned -7.4% over the past year.
  • A71 outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
A71
Industry
5yr Volatility vs Market

Value

 Is Ascendis Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ascendis Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ascendis Pharma.

DB:A71 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:A71
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 22%) (0.68%))
1.036
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.036 * 5.44%)
5.25%

Discounted Cash Flow Calculation for DB:A71 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ascendis Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:A71 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 5.25%)
2020 -264.80 Analyst x3 -251.60
2021 -293.82 Analyst x5 -265.26
2022 -228.73 Analyst x4 -196.20
2023 -80.25 Analyst x2 -65.41
2024 246.70 Analyst x3 191.05
2025 390.35 Est @ 58.23% 287.23
2026 549.00 Est @ 40.64% 383.83
2027 704.54 Est @ 28.33% 468.03
2028 843.45 Est @ 19.72% 532.38
2029 958.87 Est @ 13.68% 575.07
Present value of next 10 years cash flows €1,659.00
DB:A71 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €958.87 × (1 + -0.39%) ÷ (5.25% – -0.39%)
€16,948.20
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €16,948.20 ÷ (1 + 5.25%)10
€10,164.47
DB:A71 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €1,659.00 + €10,164.47
€11,823.47
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €11,823.47 / 47.99
€246.39
DB:A71 Discount to Share Price
Calculation Result
Exchange Rate EUR/USD
(Reporting currency to currency of NasdaqGS:ASND)
1.087
Value per Share
(USD)
= Value per Share in EUR x Exchange Rate (EUR/USD)
= €246.39 x 1.087
$267.94
Non-primary Listing Adjustment Factor 1 share in DB:A71 represents 0.92646x of NasdaqGS:ASND
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.92646x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 267.94 x 0.92646
€248.23
Value per share (EUR) From above. €248.23
Current discount Discount to share price of €113.00
= -1 x (€113.00 - €248.23) / €248.23
54.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Ascendis Pharma is available for.
Intrinsic value
>50%
Share price is €113 vs Future cash flow value of €248.23
Current Discount Checks
For Ascendis Pharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Ascendis Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Ascendis Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ascendis Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ascendis Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:A71 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-4.69
NasdaqGS:ASND Share Price ** NasdaqGS (2020-04-08) in USD $121.97
NasdaqGS:ASND Share Price converted to EUR reporting currency Exchange rate (USD/ EUR) 0.92 €112.16
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ascendis Pharma.

DB:A71 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ASND Share Price ÷ EPS (both in EUR)

= 112.16 ÷ -4.69

-23.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ascendis Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Ascendis Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Ascendis Pharma's expected growth come at a high price?
Raw Data
DB:A71 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -23.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
38.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ascendis Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ascendis Pharma's assets?
Raw Data
DB:A71 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €12.44
NasdaqGS:ASND Share Price * NasdaqGS (2020-04-08) in USD $121.97
NasdaqGS:ASND Share Price converted to EUR reporting currency Exchange rate (USD/ EUR) 0.92 €112.16
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:A71 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ASND Share Price ÷ Book Value per Share (both in EUR)

= 112.16 ÷ 12.44

9.01x

* Primary Listing of Ascendis Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ascendis Pharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Ascendis Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Ascendis Pharma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Ascendis Pharma expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ascendis Pharma expected to grow at an attractive rate?
  • Ascendis Pharma's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Ascendis Pharma's earnings growth is expected to exceed the Germany market average.
  • Ascendis Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:A71 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:A71 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 38.3%
DB:A71 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 55.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:A71 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:A71 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,100 204 326 5
2023-12-31 583 -32 17 5
2022-12-31 203 -231 -243 8
2021-12-31 56 -272 -308 10
2020-12-31 10 -239 -278 12
2020-04-08
DB:A71 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 13 -176 -218
2019-09-30 21 -162 -170
2019-06-30 19 -149 -178
2019-03-31 16 -163 -142
2018-12-31 11 -139 -130
2018-09-30 0 -127 -132
2018-06-30 1 -107 -132
2018-03-31 1 -111 -140
2017-12-31 2 -95 -124
2017-09-30 2 -88 -106
2017-06-30 3 -78 -91
2017-03-31 4 -67 -73

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ascendis Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Ascendis Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:A71 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Ascendis Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:A71 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 6.21 16.08 2.08 5.00
2023-12-31 0.47 4.40 -3.74 5.00
2022-12-31 -4.44 -1.04 -6.91 7.00
2021-12-31 -5.76 -4.16 -8.65 9.00
2020-12-31 -5.59 -4.23 -6.98 10.00
2020-04-08
DB:A71 Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -4.69
2019-09-30 -3.76
2019-06-30 -4.09
2019-03-31 -3.37
2018-12-31 -3.17
2018-09-30 -3.32
2018-06-30 -3.53
2018-03-31 -3.98
2017-12-31 -3.68
2017-09-30 -3.31
2017-06-30 -3.00
2017-03-31 -2.58

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ascendis Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Ascendis Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ascendis Pharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Ascendis Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ascendis Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ascendis Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Ascendis Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ascendis Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Ascendis Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ascendis Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:A71 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 13.38 -218.02 48.47 191.62
2019-09-30 21.38 -169.63 39.77 179.34
2019-06-30 19.16 -178.49 36.57 164.59
2019-03-31 15.97 -142.36 30.83 161.00
2018-12-31 10.58 -130.10 25.06 140.28
2018-09-30 0.35 -132.29 20.77 130.32
2018-06-30 0.76 -132.20 16.81 127.88
2018-03-31 1.19 -140.13 14.82 109.52
2017-12-31 1.53 -123.90 13.48 99.59
2017-09-30 2.29 -106.17 12.68 91.55
2017-06-30 3.03 -90.55 12.48 78.99
2017-03-31 3.72 -73.13 11.92 70.39
2016-12-31 4.61 -68.51 11.50 66.02
2016-09-30 5.54 -64.05 11.69 58.55
2016-06-30 6.49 -53.11 10.44 50.07
2016-03-31 7.30 -54.86 9.92 49.44
2015-12-31 8.12 -32.92 9.42 40.53
2015-09-30 8.97 -25.97 8.31 35.53
2015-06-30 10.10 -20.64 8.47 31.43
2015-03-31 12.07 -7.73 7.73 23.47
2014-12-31 13.98 -9.66 6.27 19.70
2014-09-30 16.72 -2.37 4.46 14.90
2014-06-30 19.53 0.33 3.50 14.66
2014-03-31 20.01 3.02 2.72 13.12
2013-12-31 20.41 4.08 2.42 12.71

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ascendis Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ascendis Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ascendis Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ascendis Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ascendis Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Ascendis Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ascendis Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ascendis Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ascendis Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ascendis Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Ascendis Pharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ascendis Pharma Company Filings, last reported 3 months ago.

DB:A71 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 597.11 0.00 598.11
2019-09-30 660.93 0.00 658.66
2019-06-30 675.08 0.00 690.36
2019-03-31 716.66 0.00 696.66
2018-12-31 280.05 0.00 277.86
2018-09-30 304.21 0.00 310.33
2018-06-30 332.23 0.00 352.60
2018-03-31 347.41 0.00 348.41
2017-12-31 187.21 0.00 195.35
2017-09-30 202.15 0.00 206.29
2017-06-30 126.47 0.00 127.32
2017-03-31 154.83 0.00 157.65
2016-12-31 176.61 0.00 180.33
2016-09-30 74.40 0.00 74.53
2016-06-30 90.91 0.00 90.75
2016-03-31 101.91 0.00 101.87
2015-12-31 120.33 0.00 119.65
2015-09-30 131.72 0.00 128.25
2015-06-30 135.73 0.00 137.85
2015-03-31 149.19 0.00 153.45
2014-12-31 45.81 0.00 50.17
2014-09-30 2.50 0.00 7.91
2014-06-30 4.14 0.00 11.76
2014-03-31 6.30 0.00 19.43
2013-12-31 6.30 0.00 19.43
  • Ascendis Pharma has no debt.
  • Ascendis Pharma has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ascendis Pharma has sufficient cash runway for more than 3 years based on current free cash flow.
  • Ascendis Pharma has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 40.3% each year.
X
Financial health checks
We assess Ascendis Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ascendis Pharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Ascendis Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ascendis Pharma dividends. Estimated to be 0% next year.
If you bought €2,000 of Ascendis Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ascendis Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ascendis Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:A71 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:A71 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ascendis Pharma has not reported any payouts.
  • Unable to verify if Ascendis Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ascendis Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ascendis Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Ascendis Pharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Ascendis Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ascendis Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ascendis Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Ascendis Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jan Mikkelsen
COMPENSATION €0
AGE 59
TENURE AS CEO 12.3 years
CEO Bio

Mr. Jan Møller Mikkelsen serves as the Chief Executive Officer, President, Executive Director and Member of Executive Board of Ascendis Pharma A/S since December 2007. Mr. Mikkelsen served as Chief Executive Officer and President at Veloxis Pharmaceuticals A/S until August 2006. He served as President of Maxygen's Protein Pharma Division and Managing Director of Maxygen APS. In this capacity, he was responsible for an organization of about 80 people and 15 drug discovery and development projects. He Co-Founded ProFound Pharma A/S and served as its Co-Chief Executive Officer from 1999 to 2000. Mr. Mikkelsen served as Managing Director of Maxygen ApS. From 1989 to 1999, he served at Novo Nordisk A/S in various positions, including Director of Protein Discovery, heading a multinational organization of more than 150 people and was a member of enzyme research management. Mr. Mikkelsen serves as Chairman of HyScite Discovery. He serves as Director of Ascendis Pharma A/S since December 2007 and served as a Director of Nuevolution A/S. Mr. Mikkelsen served as Member of Advisory Team at Nordic Biotech. He holds an M.Sc. in Biochemistry from the University of Odense.

CEO Compensation
  • Insufficient data for Jan to compare compensation growth.
  • Insufficient data for Jan to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Ascendis Pharma management team in years:

4.7
Average Tenure
53
Average Age
  • The tenure for the Ascendis Pharma management team is about average.
Management Team

Michael Jensen

TITLE
Chairman
AGE
48
TENURE
6.8 yrs

Jan Mikkelsen

TITLE
President
AGE
59
TENURE
12.3 yrs

Scott Smith

TITLE
CFO, Senior VP & Member of Executive Board
AGE
45
TENURE
3.7 yrs

Peter Rasmussen

TITLE
VP of Finance & Principal Accounting Officer
AGE
50
TENURE
6.1 yrs

Lotte Sønderbjerg

TITLE
Chief Administrative Officer & Senior VP
AGE
58
TENURE
12.3 yrs

Ami Knoefler

TITLE
Head of Global Communications

Flemming Jensen

TITLE
Senior Vice President of Product Supply
AGE
58
TENURE
4.7 yrs

Kennett Sprogøe

TITLE
Senior VP and Head of Innovation & Research
AGE
40
TENURE
4.3 yrs

Tom Larson

TITLE
Senior VP & Chief Commercial Officer
AGE
57
TENURE
2 yrs

Juha Punnonen

TITLE
Senior VP & Head of Oncology
AGE
53
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure and age of the Ascendis Pharma board of directors in years:

5.4
Average Tenure
54
Average Age
  • The tenure for the Ascendis Pharma board of directors is about average.
Board of Directors

Michael Jensen

TITLE
Chairman
AGE
48
TENURE
12.3 yrs

Jan Mikkelsen

TITLE
President
AGE
59
TENURE
12.3 yrs

Jim Healy

TITLE
Independent Director
COMPENSATION
€57K
AGE
54
TENURE
5.4 yrs

Albert Cha

TITLE
Independent Director
COMPENSATION
€51K
AGE
47
TENURE
5.4 yrs

Lars Holtug

TITLE
Independent Director
COMPENSATION
€8K
AGE
60
TENURE
1.4 yrs

Birgitte Volck

TITLE
Independent Director
COMPENSATION
€39K
AGE
57
TENURE
3.9 yrs

Lisa Morrison

TITLE
Independent Director
COMPENSATION
€43K
AGE
51
TENURE
3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Mar 20 Sell OrbiMed Advisors LLC Company 02. Mar 20 04. Mar 20 -55,700 €121.78 €-6,715,858
14. Aug 19 Sell OrbiMed Advisors LLC Company 14. Aug 19 14. Aug 19 -32,900 €102.96 €-3,387,341
X
Management checks
We assess Ascendis Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ascendis Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone has completed Phase I clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. The company was founded in 2006 and is headquartered in Hellerup, Denmark.

Details
Name: Ascendis Pharma A/S
A71
Exchange: DB
Founded: 2006
$5,382,264,802
47,985,837
Website: http://www.ascendispharma.com
Address: Ascendis Pharma A/S
Tuborg Boulevard 12,
Hellerup,
Capital Region of Denmark, 2900,
Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ASND ADR REPR 1 ORD SHARES DKK1.00 Nasdaq Global Select US USD 28. Jan 2015
DB A71 ADR REPR 1 ORD SHARES DKK1.00 Deutsche Boerse AG DE EUR 28. Jan 2015
BMV ASND N ADR REPR 1 ORD SHARES DKK1.00 Bolsa Mexicana de Valores MX MXN 28. Jan 2015
Number of employees
Current staff
Staff numbers
330
Ascendis Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:02
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/04/03
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.